The leaves of Mitragyna
speciosa (kratom), a plant native to Southeast Asia,
are increasingly used
as a pain reliever and for attenuation of opioid withdrawal symptoms.
Using the tools of natural products chemistry, chemical synthesis,
and pharmacology, we provide a detailed in vitro and in vivo pharmacological characterization of the alkaloids
in kratom. We report that metabolism of kratom’s major alkaloid,
mitragynine, in mice leads to formation of (a) a potent mu opioid
receptor agonist antinociceptive agent, 7-hydroxymitragynine, through
a CYP3A-mediated pathway, which exhibits reinforcing properties, inhibition
of gastrointestinal (GI) transit and reduced hyperlocomotion, (b)
a multifunctional mu agonist/delta-kappa antagonist, mitragynine pseudoindoxyl,
through a CYP3A-mediated skeletal rearrangement, displaying reduced
hyperlocomotion, inhibition of GI transit and reinforcing properties,
and (c) a potentially toxic metabolite, 3-dehydromitragynine, through
a non-CYP oxidation pathway. Our results indicate that the oxidative
metabolism of the mitragynine template beyond 7-hydroxymitragynine
may have implications in its overall pharmacology in vivo.